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Marked and rapid decreases of circulating leptin
in streptozotocin diabetic rats: reversal by insulin
PETER J. HAVEL, JANET Y. URIU-HARE, TINA LIU, KIMBER L. STANHOPE,
JUDITH S. STERN, CARL L. KEEN, AND BO AHRE´N
Department of Nutrition, University of California, Davis, California 95616;
and Department of Medicine, Lund University, S-20502 Malmo¨, Sweden
Havel, Peter J., Janet Y. Uriu-Hare, Tina Liu, Kimber
L. Stanhope, Judith S. Stern, Carl L. Keen, and Bo
Ahre´n. Marked and rapid decreases of circulating leptin in
streptozotocin diabetic rats: reversal by insulin. Am. J.
Physiol. 274 (Regulatory Integrative Comp. Physiol. 43):
R1482–R1491, 1998.—Evidence for regulation of circulating
leptin by insulin is conflicting. Diabetes was induced in rats
with streptozotocin (STZ; 40 mg·kg21 ·day21 3 2 days) to
examine the effect of insulin-deficient diabetes and insulin
treatment on circulating leptin. After 12 wk, plasma leptin
concentrations in untreated rats were all ,0.4 ng/ml versus
4.9 6 0.9 ng/ml in control animals (P , 0.005). In rats treated
with subcutaneous insulin implants for 12 wk, which reduced
hyperglycemia by ,50%, plasma leptin was 2.1 6 0.6 ng/ml,
whereas leptin concentrations were 6.0 6 1.6 ng/ml in
insulin-implanted rats receiving supplemental injections of
insulin for 4 days to normalize plasma glucose (P , 0.005 vs.
STZ untreated). In a second experiment, plasma leptin was
monitored at biweekly intervals during 12 wk of diabetes. In
rats treated with insulin implants, plasma leptin concentra-
tions were inversely proportional to glycemia (r 5 20.64; P ,
0.0001) and unrelated to body weight (P 5 0.40). In a third
experiment, plasma leptin concentrations were examined
very early after the induction of diabetes. Within 24 h after
STZ injection, plasma insulin decreased from 480 6 30 to
130 6 10 pM (P , 0.0001), plasma glucose increased from
7.0 6 0.2 to 24.8 6 0.5 mM, and plasma leptin decreased from
3.2 6 0.2 to 1.2 6 0.1 ng/ml (D 5 263 6 3%, P , 0.0001). In a
subset of diabetic rats treated with insulin for 2 days, glucose
decreased to 11.7 6 3.9 mM and leptin increased from 0.5 6
0.1 to 2.9 6 0.6 ng/ml (P , 0.01) without an effect on
epididymal fat weight. The change of leptin was correlated
with the degree of glucose lowering (r 5 0.75, P , 0.05). Thus
insulin-deficient diabetes produces rapid and sustained de-
creases of leptin that are not solely dependent on weight loss,
whereas insulin treatment reverses the hypoleptinemia. We
hypothesize that decreased glucose transport into adipose
tissue may contribute to decreased leptin production in
insulin-deficient diabetes.
glucose; C-peptide; food intake; epididymal fat
LEPTIN, THE PRODUCT of the ob gene (48), has been
implicated in the regulation of feeding behavior and
body adiposity (7). Circulating leptin concentrations
correlate with adiposity in both humans (10, 18, 29)
and rodents (1, 29) and decrease after fasting (1, 3, 5,
46), energy restriction (13), or weight loss (10, 18). Thus
leptin may act as a signal from peripheral adipose
stores to the central nervous system to decrease food
intake, increase energy expenditure, and limit adipos-
ity (7). Conversely, low leptin concentrations after
fasting or energy restriction may act to increase food
intake and decrease energy expenditure (7) as well as
to regulate neuroendocrine and reproductive function
(3). However, the factors involved in the physiological
regulation of leptin secretion and circulating leptin
concentrations are not well defined.
Plasma leptin concentrations are correlated with
plasma insulin concentrations in humans and animals
(1, 18) and are related to indexes of insulin secretion
and negatively correlated with insulin sensitivity, inde-
pendent of adiposity, in humans (26). Changes of plasma
leptin after fasting in animals (1) or after weight loss in
humans (18) are correlated with changes of plasma
insulin independent of changes in adiposity. In addi-
tion, decreases of circulating leptin during energy
restriction in human subjects are related to changes of
insulin and glucose (13), and glucose infusions that
prevent the decreases of insulin and glucose during
fasting also prevent the decline of circulating leptin (5).
Furthermore, nocturnal increases of plasma leptin
concentrations in humans (40) are proportional to
insulin responses to meals (27).
Thus, based on the relationship between circulating
insulin and leptin concentrations, insulin is a candi-
date as a hormonal regulator of leptin synthesis and/or
secretion. Although several studies investigating the
effect of insulin administration on circulating leptin
have found no changes of plasma leptin during short-
term hyperinsulinemic euglycemia or hypoglycemic
clamps (12, 23, 26, 34), in one study, long-term (72 h)
insulin infusion modestly increased plasma leptin (23).
Two other studies examined the effects of high-dose
insulin and glucose infusion and found increased plasma
leptin after 4–6 h in nondiabetic (45) and diabetic (19)
human subjects. These infusions, however, produced
markedly supraphysiological insulin concentrations and
required the administration of large amounts of glucose
to prevent hypoglycemia. Thus these studies did not
address whether the increases of circulating leptin
were due to a direct effect of insulin per se or an indirect
effect via insulin’s action to increase adipose glucose
uptake. We have recently reported that glucose uptake
and metabolism are involved in regulating leptin expres-
sion and secretion in cultured rat adipocytes (31).
Several studies have found that ob gene expression is
increased after insulin (11, 16, 30, 35) or glucose (30)
administration and decreased in insulin-deficient dia-
betic animals (4, 28, 42); however, changes of circulat-
ing leptin concentrations after induction of diabetes
and plasma leptin responses to insulin administration
in diabetic rodents have not been previously reported.
Furthermore, dissociations between changes of ob gene
expression and circulating leptin concentrations have
recently been described (22), suggesting that leptin
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expression and secretion can be differentially regu-
lated.
Therefore, the goals of the present study were to
examine the effects and time course of insulin-deficient
diabetes induced by streptozotocin (STZ) on circulating
leptin concentrations, the effects of short-term and
long-term exogenous insulin treatment on plasma lep-
tin, and the relationship of plasma leptin to changes of
glycemia in STZ diabetic rats. STZ diabetes results in
weight loss. Because loss of body fat would be expected
to reduce circulating leptin concentrations, we also
examined plasma leptin very early after the induction
of diabetes, before the onset of significant weight loss.
METHODS
Animals
Adult male Sprague-Dawley rats (Charles River) weighing
340–490 g were used for the studies. The animals were
individually housed in hanging wire cages and fed a standard
commercial diet (no. 557; Ralston Purina, Belmont, CA) and
deionized water ad libitum. The light-dark cycle was 12 h
with lights on and 12 h with lights off, with lights on at 0600.
Experimental protocols were approved by the Institutional
Animal Use and Care Committee of the University of Califor-
nia, Davis and were conducted in accordance with the Na-
tional Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Induction of Diabetes
Insulin-deficient diabetes was induced with subcutaneous
injections of freshly prepared STZ (Sigma, St. Louis, MO) at a
dose of 40 mg/kg in ice-cold 0.5 mol/l citrate buffer (pH 4.5). A
second dose of STZ (40 mg/kg) was administered 24 h later.
This regimen produces insulin-deficient diabetes (plasma
glucose .25 mmol/l) in .95% of treated animals without
inducing renal failure or losses from hypoglycemia (2). Con-
trol animals received injections of citrate buffer only. Three
separate experiments were conducted in STZ diabetic rats:
two long-term 12-wk studies and one short-term 2-wk study.
Protocols
Experiment 1. To examine plasma leptin after long-term
(12 wk) STZ diabetes and the effects of two levels of insulin
treatment designed to either reduce or normalize plasma
glucose concentrations on circulating leptin, diabetes was
induced with STZ in 24 rats as described in Induction of
Diabetes. Twelve buffer-injected rats served as nondiabetic
controls. At the time of the second STZ injection, 14 of the
diabetic animals received 1.25 implants impregnated with
bovine insulin (Linplant, Toronto, ON, Canada) placed subcu-
taneously through a 14-gauge needle under light ketamine-
xylazine (30:10 mg/kg, respectively) anesthesia. These im-
plants slowly release insulin (,2 U/day) for up to 40 days. The
control and 10 other STZ diabetic rats were sham implanted.
Plasma glucose was monitored 1–2 times weekly from a tail
blood sample (,0.5 ml) collected in a heparinized tube
(Sarstedt, Hayward, CA) during brief restraint (,2 min) in a
polyethylene rodent restraint cone. Plasma glucose was mark-
edly elevated (.25 mmol/l) in all of the untreated STZ
diabetic rats. The implanted animals were reimplanted with
an additional 0.5–2 implants to maintain a moderate reduc-
tion of plasma glucose (,10 mmol/l less than untreated rats).
The untreated STZ diabetic rats all received one-third of an
insulin implant at 6 wk after the induction of diabetes to
prevent marked weight loss and debilitation. The animals
were weighed weekly, and food intake was determined periodi-
cally during the experiment. After 11 wk, 7 of the 14 im-
planted animals received daily injections of bovine ultra lente
insulin (9–26 U·kg21 ·day21) to normalize the plasma glucose
over 7 days. After 12 wk, all animals were anesthetized with
chloral hydrate (350 mg/kg) and a blood sample (3.0 ml) was
obtained between 1000 and 1400 by cardiac puncture with a
21-gauge needle before the pancreas was isolated and per-
fused for another study.
Experiment 2. To examine plasma leptin over the course of
long-term (12 wk) STZ diabetes and its relationship to
glycemic control during insulin treatment, diabetes was
induced in 29 rats. Eighteen buffer-injected rats served as
nondiabetic controls. Plasma glucose was monitored weekly
by tail bleeding as described in experiment 1. Seventeen of
the diabetic rats received 1.25 subcutaneous insulin implants
after the second STZ injection as described in experiment 1.
After 3 wk, plasma glucose concentrations were increasing.
Therefore, an additional one to two implants (mean 5 1.5)
were placed after 3 wk. Most of the animals (14 of 17) received
an additional implant after 8 wk to maintain a moderate
reduction of plasma glucose (see Fig. 2A). Twelve of the STZ
diabetic rats were untreated except for 0.5 implants placed 6
wk after the induction of diabetes. The animals were weighed
weekly, and food intake was measured over 2 days every 2 wk
during the experiment. Blood samples (1.8 ml) for the mea-
surement of plasma leptin were obtained from nonfasted
animals between 1000 and 1200 by tail bleeding, at biweekly
intervals over the 12 wk of the experiment, into heparinized
tubes containing 30 µl of aprotinin (Sigma) solution per
milliliter of whole blood collected. A total of 10.8 ml was
obtained over the first 10 wk of the study. A final blood sample
(2.0 ml) was collected between 1000 and 1400 by cardiac
puncture after 12 wk as described for experiment 1.
Experiment 3. To examine plasma leptin concentrations
and their relationship to other parameters very early after
the induction of STZ diabetes, diabetes was induced in 22 rats
as described in Induction of Diabetes. Fourteen buffer-
injected animals served as nondiabetic controls. Body weight,
food intake, and water intake were measured for 2 days
before the induction of diabetes and for the 14-day duration of
the experiment. A baseline blood sample (1.0 ml) for measure-
ment of plasma glucose, insulin, and leptin was collected
before the initial injection of STZ, and additional 1.0-ml
samples were taken at 1, 2, 3, 5, 8, 11, and 14 days after STZ
for a total of 8.0 ml of blood over 2 wk. All blood samples were
taken in the nonfasted state between 0800 and 1000. A subset
of diabetic animals (n 5 8) received twice-daily injections of
lente insulin at 0800 and 1800 on days 14–16. On day 16,
eight of the control rats, seven untreated diabetic rats, and
the eight insulin-treated STZ diabetic rats were anesthetized
with halothane and a final blood sample (3.0 ml) was collected
via cardiac puncture. The animals were euthanized, and the
liver, kidneys, and epididymal fat depots were removed and
weighed.
Assays and Data Analysis
Plasma glucose was measured by the glucose oxidase
method with a glucose analyzer 2700 (Yellow Springs Instru-
ments). Plasma nonesterified fatty acid (NEFA) concentra-
tions were measured with a kit from Waco (Richmond, VA).
Plasma insulin and C-peptide were measured by radioimmu-
noassays specific for rat insulin and C-peptide with reagents
from Linco Research (St. Charles, MO). The lower limits of
detection for the rat insulin and C-peptide assays are 0.1
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ng/ml and 40 pM, respectively. Plasma leptin was measured
with a radioimmunoassay for mouse leptin with reagents
from Linco Research as previously described (1). Plasma
leptin concentrations measured with this assay are propor-
tional to those obtained with a newly developed assay specific
for rat leptin (25). Measured leptin concentrations were
highly correlated between the two assays (r 5 0.94, P ,
0.0001). Measurements of rat plasma leptin made with the
mouse assay therefore provide reliable estimates of rat leptin
concentrations. The intra- and interassay coefficients of varia-
tion for the mouse assay are 4.0 and 11.2%, respectively (1),
with a lower limit of detection of 0.2 ng/ml. The antibody used
in the assay does not cross-react with insulin, pro-insulin,
glucagon, pancreatic polypeptide, or somatostatin.
Data are expressed as means 6 SE. Statistical analyses
were performed using a software package (StatView for
Macintosh; Abacus, Berkeley, CA). Means within a group
were compared with a paired t-test. For comparisons of more
than two groups, analysis of variance (ANOVA) was used with
Dunnett’s post test. Both simple and multiple linear regres-
sion analyses were performed.
RESULTS
Experiment 1
Long-term effects of STZ diabetes and insulin treat-
ment on plasma leptin concentrations. Body weight,
food intake, plasma insulin, and C-peptide values
measured after 12 wk of diabetes in the four groups of
animals are provided in Table 1. As expected, untreated
STZ diabetic rats were markedly hyperglycemic. Plasma
glucose in insulin-implanted rats was significantly
reduced compared with untreated animals but still
elevated compared with nondiabetic control rats (Fig.
1A). Plasma glucose was normalized to control levels in
insulin-implanted rats receiving insulin injections (Fig.
1A). Plasma leptin was ,0.5 ng/ml (,10% of mean
control values) in all untreated STZ diabetic rats. In
insulin-implanted diabetic rats, plasma leptin concen-
trations were 42 6 13% of those in control animals.
Plasma leptin was restored to levels equivalent to those
in control animals (122 6 34% of control) in insulin-
implanted animals receiving 7 days of supplemental
insulin injections (Fig. 1B). Overall, plasma leptin after
12 wk was positively correlated with body weight (r 5
0.69, P , 0.0001) and the change of body weight over 12
wk (r 5 0.71, P , 0.0001) and negatively correlated
with food intake (r 5 20.45, P , 0.01), plasma glucose
(r 5 20.60, P , 0.0002), plasma insulin (r 5 20.49, P ,
0.0025), and plasma C-peptide (r 5 20.38, P , 0.025).
Experiment 2
Time course of plasma leptin concentrations over 12
wk of insulin-treated STZ diabetes. In control rats,
plasma glucose was stable at 7.1–8.3 mmol/l (Fig. 2A).
The initial plasma leptin concentrations averaged 5.4 6
0.5 ng/ml and remained between 5.1 and 7.5 ng/ml for
the 12 wk of the experiment (Fig. 2B). Body weight in
control rats was increased by 50 6 3 g after 2 wk and
Table 1. Body weight, food intake, plasma insulin, and
C-peptide after 12 wk of diabetes
Control
Nondiabetic
(n511)
STZ
Untreated
(n510)
STZ
Implanted
(n57)
STZ
Implanted
1Insulin
Injected
(n57)
Body wt, g
(initial) 40466 40164 40164 39867
Body wt, g
(12 wk) 631622 465613‡ 551617* 615625
DBody wt, g/
12 wk 227618 65611‡ 150614† 217620
Food intake,
g/day 3261 6564‡ 3862 ND
[Insulin], pmol/l 188622 46615* 1,0216305† 1,0806451†
[C-peptide],
pmol/l 591672 4966‡ 78617† ,40‡
Values are means 6 SE; n 5 no. of rats. Nondiabetic control,
untreated streptozotocin (STZ) diabetic, insulin-implanted STZ dia-
betic, and insulin-implanted diabetic rats treated with daily insulin
injections from week 11 to week 12 (experiment 1). Plasma glucose and
leptin concentrations (brackets) from these animals are included in
Fig. 1. ND, not done. *P , 0.025, †P , 0.005, ‡P , 0.001 vs. control.
Fig. 1. Twelve-week plasma glucose (A) and leptin (B) concentra-
tions in 12 nondiabetic (control) rats, 10 untreated streptozotocin
(STZ) diabetic rats, 7 STZ diabetic rats with bovine insulin implants
(Imp), and 7 insulin-implanted STZ diabetic rats also treated with
insulin injections (Imp 1 Inj) to normalize plasma glucose concentra-
tions. *P , 0.025 vs. control.
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continued to increase throughout the experiment, reach-
ing 633 6 12 g by 12 wk. In untreated diabetic rats,
plasma glucose was increased to ,30 mmol/l at 2 wk
after the induction of diabetes and remained elevated
throughout the 12 wk of the experiment (Fig. 2A).
Plasma leptin in untreated diabetic rats decreased to
1.0 6 0.1 ng/ml by 2 wk (P , 0.0001 vs. control; Fig.
2B), whereas body weight increased by only 8 6 3 g
during this time (P , 0.0001 vs. control). In STZ
diabetic rats with insulin implants, plasma glucose 2
wk after induction of diabetes was lower than in
untreated diabetic rats (20.1 6 1.6 mmol/l; Fig. 2A),
and plasma leptin (Fig. 2B) and body weight gain were
intermediate between control and untreated diabetic
rats, averaging 2.3 6 0.2 ng/ml and 24 6 3 g, respec-
tively.
After 3 wk, the insulin-implanted diabetic rats re-
ceived an additional 1–2 insulin implants, which nor-
malized plasma glucose concentrations at 7.5 6 1.4
mmol/l at 4 wk (Fig. 2A). Plasma leptin increased to
4.6 6 0.5 ng/ml at this time (Fig. 2B). Plasma glucose in
this group of animals increased moderately at 6 wk and
more so from 8 to 12 wk into the study. Plasma leptin
concentrations in insulin-implanted diabetic rats essen-
tially mirrored plasma glucose concentrations through-
out the study (Fig. 2, A and B). Body weight in
insulin-implanted diabetic rats increased progressively
but remained intermediate between the control and
untreated diabetic animals.
Relationship between plasma leptin, plasma glucose,
and body weight over 12 wk of STZ diabetes. Across all
three groups of rats, mean plasma leptin concentra-
tions over 12 wk were significantly correlated with
mean body weight (r 5 0.62, P , 0.0001) and negatively
correlated with plasma glucose (r 5 20.78, P , 0.0001)
by simple linear regression. However, by multiple
regression analysis, mean plasma leptin concentra-
tions were significantly related to mean plasma glucose
concentrations (P , 0.0001) but not to mean body
weight (P 5 0.42). When all six time points in the three
groups of rats were examined, the individual plasma
leptin concentrations were significantly correlated with
both body weight (r 5 0.66, P , 0.0001) and plasma
glucose (r 5 0.74, P , 0.0001) by simple and by multiple
regression analysis (r 5 0.78, P , 0.0001); however, the
t-statistic was larger for plasma glucose (t 5 10.04)
than for body weight (t 5 6.19). When these compari-
sons were made only in the group of STZ diabetic rats
treated with insulin implants, plasma leptin concentra-
tions over the six time points were negatively corre-
lated with plasma glucose (r 5 20.64, P , 0.0001; Fig.
3) but not body weight (r 5 0.14, not significant) by
simple regression analysis. Similarly, by multiple re-
gression analysis, plasma leptin concentrations were
related to plasma glucose concentrations (P , 0.0001)
but not to body weight (P 5 0.40).
Experiment 3
Short-term effects of STZ diabetes and insulin treat-
ment on plasma leptin concentrations. BASELINE CORRE-
LATIONS. Baseline characteristics of the animals studied
in experiment 3 before the induction of diabetes are
Fig. 2. Biweekly plasma glucose (A) and leptin (B) concentrations in
nondiabetic (control) rats, untreated (no TX) STZ diabetic rats, and
STZ diabetic rats treated with bovine insulin implants over 12 wk
after STZ or vehicle injection.
Fig. 3. Relationship between plasma glucose and leptin concentra-
tions in 22 STZ diabetic rats treated with bovine insulin implants
over the course of 12 wk of STZ diabetes. Plasma glucose varied
widely in these animals over the 12 wk (see Fig. 2B).
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included in Table 2. Baseline body weight in nonfasted
animals was significantly correlated with plasma lep-
tin concentrations (r 5 0.43, P , 0.01) but not with
plasma insulin (r 5 0.07, P 5 0.71) or plasma glucose
concentrations (r 5 0.05, P 5 0.79). Baseline plasma
leptin was significantly correlated with plasma insulin
(r 5 0.46, P , 0.005) but not with plasma glucose (r 5
0.13, P 5 0.45). Baseline plasma insulin was not
correlated with baseline plasma glucose concentrations
(r 5 0.06, P 5 0.72).
CHANGES AFTER THE INDUCTION OF DIABETES. Means of
all parameters measured before and 14 days after the
administration of STZ or vehicle (control animals) are
provided in Table 2. The time courses of the changes in
insulin, glucose, and leptin are shown in Figs. 4–6.
Plasma insulin fell by 20% within 24 h of the first STZ
injection (P , 0.02) and by 72 6 3% (P , 0.0001) after
48 h and a second injection of STZ. Thereafter, plasma
insulin remained at ,20% of baseline concentrations
(Fig. 4) despite marked hyperglycemia. Plasma glucose
increased to 22.2 6 1.3 mM 24 h after the first STZ
injection (P , 0.0001) and continued to be elevated at
.25 mM for the 14 days of the study (Fig. 5). Water
intake increased progressively from the induction of
diabetes throughout the 14 days of the experiment
(Table 2). Body weight decreased slightly (,3%) 24 h
after the first STZ injection and by 9% 24 h after the
second injection.
Plasma leptin decreased 43 6 4% (P , 0.0001) 24 h
after STZ administration and by 63 6 3% (P , 0.0001)
after 48 h and a second STZ injection. At 72 h, plasma
leptin was decreased by 73 6 2% (P , 0.0001) and
remained ,75% of baseline concentrations for the 14
days of the study (Fig. 6). By simple linear regression,
the change of plasma leptin at 24 h after STZ was
significantly correlated with the changes of plasma
glucose (r 5 0.69, P , 0.0005), plasma insulin (r 5 0.58,
P , 0.005), and body weight (r 5 0.69, P , 0.0005).
However, by multiple regression, the change of leptin
correlated with the change of glucose (P 5 0.018) but
not the change of insulin (P 5 0.14) or the change of
body weight (P 5 0.56). Food intake was initially
reduced by ,20% after STZ injection but recovered to
that of control rats by day 3. STZ diabetic rats were
hyperphagic relative to nondiabetic control animals by
day 4. Food intake in the diabetic animals increased
progressively thereafter and was approximately double
that in control rats from days 8–14 (Table 2).
EFFECTS OF EXOGENOUS INSULIN ADMINISTRATION. A
subset of eight STZ diabetic rats from experiment 3
was treated with insulin for 2 days from day 14 to day
16. Responses to insulin treatment are included in
Table 3. Parameters examined in the insulin-treated
STZ diabetic rats were compared with those in control
and untreated diabetic rats after 16 days in Table 4.
After 2 days of insulin injections, plasma glucose was
reduced by ,60% and plasma leptin was increased by
nearly 500%. Body weight was increased by ,3%. Food
Fig. 4. Plasma insulin concentrations in nondiabetic (control) rats
and untreated STZ diabetic rats before and after induction of
diabetes. Arrows indicate injection times.
Fig. 5. Plasma glucose concentrations in nondiabetic (control) rats
and untreated STZ diabetic rats before and after induction of
diabetes. Arrows indicate injection times.
Table 2. Body weight, food intake, H2O intake, plasma
insulin, glucose, and leptin before and after 14 days in
nondiabetic rats and STZ diabetic rats (experiment 3)
Control
(n514)
STZ Diabetic
(n522)
Body wt, g 43369 43867
Body wt (14 days), g 475612 42267*
DBody wt, g 14266* 21565†‡
Food intake, g/day 3461 3461
Food intake (14 days), g/day 3461 7061*
DFood intake, g/day 061 13661*†
H2O intake, g/day 4863 4763
H2O intake (14 days), g/day 4362 26669*
DH2O intake, g/day 2463 121969*†
[Insulin], pmol/l 417630 482634
[Insulin] (8 days), pmol/l 365646 84610*
D[Insulin], pmol/l 252657 2398630*†
[Glucose], mmol/l 6.960.2 7.160.2
[Glucose] (14 days), mmol/l 7.160.2 27.660.7*
D[Glucose], mmol/l 10.160.2 120.660.8*†
[Leptin], ng/ml 3.260.2 3.260.2
[Leptin] (14 days), ng/ml 3.160.3 0.660.1*
D[Leptin], ng/ml 20.160.3 22.760.2*†
Values are means 6 SE; n 5 no. of rats. *P , 0.0001 vs. day 0, †P ,
0.0001 vs. control, ‡P , 0.005 vs. day 0.
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and water intake were significantly reduced by insulin
treatment (Table 3). The increase of plasma leptin
induced by insulin treatment was proportional to the
degree of glucose lowering (r 5 0.75, P , 0.05) and to
liver weight (r 5 0.70, P , 0.05) but not to the
epididymal fat depot weight (r 5 0.12, P 5 0.78).
Plasma glucose concentrations in insulin-treated dia-
betic rats were significantly lower than in untreated
diabetic rats and not different from the control rats.
Plasma leptin in insulin-treated rats was increased
compared with the untreated rats (Table 4). Plasma
NEFA was elevated twofold in untreated diabetic rats
and normalized in insulin-treated diabetic rats (Table
4). The insulin-treated rats weighed less than control
rats and were not significantly heavier than untreated
diabetic rats (Table 4). Epididymal fat depot weight
was also significantly lower in insulin-treated than in
control rats and not different from untreated diabetic
rats. Insulin-treated diabetic rats had larger livers
than control or untreated diabetic rats. Both insulin-
treated and untreated diabetic rats had larger kidneys
than nondiabetic control animals (Table 4). Insulin-
treated diabetic rats had lower food intakes compared
with untreated diabetic rats but were still hyperphagic
relative to the control animals.
In all 23 animals studied on day 16, plasma leptin
concentrations were significantly correlated with both
plasma glucose (r 5 0.76, P , 0.0001) and plasma
NEFA (r 5 0.60, P , 0.005). In addition, plasma glucose
and plasma NEFA concentrations were highly corre-
lated with each other (r 5 0.82, P , 0.0001). By
multiple regression analysis, however, plasma leptin
was correlated with plasma glucose (P , 0.005) but not
with plasma NEFA (P 5 0.71). Similarly, in these
animals, plasma leptin concentrations were signifi-
cantly correlated with both plasma glucose (r 5 0.76,
P , 0.0001) and epididymal fat depot weight (r 5 0.83,
P , 0.0001) by simple linear regression (Fig. 7, A and
B). By multiple regression analysis, plasma leptin was
significantly correlated with both epididymal fat depot
weight and plasma glucose concentrations (both P ,
0.001).
DISCUSSION
In this study, we found that circulating plasma leptin
concentrations are markedly decreased in untreated
STZ diabetic rats. Thus the effects of insulin-deficient
diabetes on plasma leptin concentrations are in agree-
ment with previous studies that showed reductions of
adipose tissue ob mRNA in STZ diabetic rats (4, 28, 42).
Plasma leptin was markedly decreased after 2 wk and
remained low through 12 wk of STZ diabetes in rats
with significantly lower body weights than in nondia-
betic control rats (experiments 1 and 2). However,
marked decreases of plasma leptin were also observed
very early (24–48 h) after the induction of diabetes
(experiment 3) and before major decreases of body
weight. These early changes of leptin were proportional
to the changes of glycemia but not to changes of body
weight. Furthermore, it is likely that the weight loss
during the first 24–48 h after induction of diabetes was
mostly due to loss of body water rather than body fat,
because diabetic rats were hyperglycemic and polydip-
sic by 24 h. Thus plasma leptin was decreased out of
proportion to the modest changes of body weight.
Plasma leptin is similarly decreased during fasting
(5, 46) or energy restriction in humans (13) and rodents
(1, 3) to a degree beyond that expected for the decreases
of body weight or fat content. Therefore, despite the
close relationship between circulating leptin concentra-
tions and adiposity, both short-term (24–48 h) diabetes
Fig. 6. Plasma leptin concentrations in nondiabetic (control) rats and
untreated STZ diabetic rats before and after induction of diabetes.
Arrows indicate injection times.
Table 3. Values before and after 2 days of insulin
administration in 8 STZ diabetic rats (experiment 3)
Before Insulin After Insulin D
[Insulin], pmol/l 9060.20 5,65062,050 15,56062,060*
[Glucose], mmol/l 27.961.3 11.763.9 216.264.7†
[Leptin], ng/ml 0.560.1 2.960.6 12.460.7†
Body wt, g 426611 437610 11164*
Food intake, g/day 7462 5962 21663‡
H2O intake, ml/day 311618 132610 2179615‡
Values are means 6 SE. *P , 0.02 vs. before insulin, †P , 0.01 vs.
before insulin, ‡P , 0.0025 vs. before insulin.
Table 4. Body weight; plasma glucose, NEFA, and
leptin; liver, kidney, and epididymal fat depot weights;
and food intake in rats after 16 days (experiment 3)
Control
Nondiabetic
(n58)
STZ
Untreated
(n57)
STZ
Insulin-Treated
(n58)
Body wt, g 489621 41466* 437610†
[Insulin], pmol/l 610670 80610* 5,56062,060†
[Glucose], mmol/l 9.460.6 29.961.2* 11.763.9‡
[NEFA], meq/l 0.3960.03 0.8560.09* 0.3460.08‡
[Leptin], ng/ml 4.760.6 0.660.1* 2.960.6§
Liver wt, g 17.361.0 18.160.6 27.062.3*‡
Kidney wt, g 3.760.2 4.760.1* 4.760.3†
Fat wt, g 7.560.7 3.160.2* 4.460.3*
Food intake, g/day 3662 7464* 5862*‡
Values are means 6 SE; n 5 no. of rats. STZ insulin-treated rats
were injected with insulin from days 14–16. NEFA, nonesterified
fatty acids. *P , 0.005 vs. control, †P , 0.025 vs. control, ‡P , 0.005
vs. STZ untreated, and §P , 0.025 vs. STZ untreated.
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and energy restriction are characterized by lower circu-
lating leptin concentrations than expected for the
amount of body fat. After 2 wk of diabetes, decreases of
plasma leptin were related to reduced adiposity, as
assessed by epididymal fat depot weight, and inversely
correlated with plasma glucose concentrations. To-
gether these data suggest that the short-term effect of
STZ-induced diabetes to decrease plasma leptin is
mainly the result of insulin deficiency and decreased
glucose uptake and metabolism (see below), whereas in
diabetes of longer duration (.2 wk), both reduced
adiposity and insulin deficiency contribute to the hypo-
leptinemia.
The relationship between adiposity, glycemia, and
circulating leptin concentrations may vary with the
time of day and the metabolic state. Sinha et al. (40)
have shown that there is a nocturnal increase of plasma
leptin concentrations in humans. The nocturnal in-
crease does not occur in fasted subjects (5) and appears
to be related to meal-induced insulin secretion and
diurnal cortisol rhythms (27). A nocturnal increase of
ob gene expression has been observed in rats (35).
Because we only measured leptin in nonfasted animals
and at one time point during a single day, it is possible
that the correlations we observed might be different if
examined at other times. For example, circulating
leptin concentrations may be most closely related to
adiposity in the fasted state but related to plasma
insulin, circulating glucose concentrations, and glucose
metabolism in the fed state. We have, however, ob-
served that in humans the relationship between fasting
leptin and serum glucose is strengthened after 7 days of
energy restriction and that the change of fasting leptin
after energy restriction is correlated with changes of
glycemia (13), suggesting that glucose metabolism may
be related to leptin both after feeding and during
fasting.
Either chronic (experiments 1 and 2) or acute (experi-
ment 3) insulin treatment increased plasma leptin in
STZ diabetic rats in proportion to the reduction of
hyperglycemia. Insulin treatment has been previously
demonstrated to increase ob mRNA in nondiabetic (11,
16, 35) rats and normalize ob mRNA expression in some
(28), but not all (4, 42), studies of STZ diabetic rats.
Dissociations between changes of ob gene expression
and changes of circulating leptin concentrations have
been reported. For example, plasma leptin increases
after dexamethasone administration in humans with-
out a corresponding increase of adipose ob mRNA (22).
It should be noted that the circulating insulin concentra-
tions produced by administering exogenous insulin to
diabetic rats in these studies were substantially higher
than in nondiabetic control animals. These levels are,
however, necessary to lower plasma glucose concentra-
tions because STZ diabetes is associated with insulin
resistance (32) in addition to insulin deficiency.
A number of published studies have found that
short-term insulin administration does not increase
plasma leptin concentrations in human subjects (12,
23, 26, 34). In contrast, some other studies have
demonstrated significant increases of circulating leptin
concentrations after 4–6 h of high-dose insulin and
glucose infusion in nondiabetic (45) and diabetic hu-
man subjects (19). Furthermore, infusions of glucose
alone, resulting in hyperglycemia and concomitant
endogenous hyperinsulinemia, increase plasma leptin
within 4 h in humans (43) and rhesus monkeys (17).
There is evidence that the induction of marked
hyperinsulinemia is not required to increase plasma
leptin concentrations. For example, low-dose glucose
infusion sufficient to prevent the decline of plasma
insulin and glucose during fasting also prevents the
decline of plasma leptin (5). In addition, lowering
plasma glucose concentrations to euglycemia in hyper-
glycemic insulin-dependent diabetic human subjects by
infusing insulin at rates that produced physiological
insulinemia increases circulating leptin (20). There-
fore, an effect of insulin to increase adipose tissue
glucose uptake and metabolism, rather than hyperinsu-
linemia per se, may be involved in stimulating leptin
secretion. Consistent with this hypothesis, we have
found that stimulation of leptin secretion by insulin
Fig. 7. Relationship between plasma glucose (A) or epididymal fat
depot weight (B) and plasma leptin concentrations after 16 days in
nondiabetic control rats, untreated STZ diabetic rats, and STZ
diabetic rats treated with twice-daily insulin injection for 2 days after
14 days of diabetes.
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from in vitro cultured rat adipocytes is closely related
to the effects of insulin to increase adipocyte glucose
uptake. In the same study, blocking glucose uptake
with 2-deoxy-D-glucose, phloretin, or cytochalasin-B or
inhibiting glucose metabolism with iodoacetate or so-
dium fluoride produced inhibitions of leptin secretion
that were related to decreased glucose utilization,
despite the presence of high insulin concentrations
(31). Thus hypoleptinemia in unregulated insulin-
deficient diabetes may be a consequence of decreased
glucose uptake and metabolism in adipose tissue,
whereas the restoration of circulating leptin levels by
insulin treatment in diabetic animals may be second-
ary to increased adipocyte glucose uptake and utiliza-
tion. We have hypothesized that similar, but less
marked, changes of adipocyte glucose metabolism may
mediate the in vivo effects of fasting and refeeding on
circulating leptin concentrations (18).
Rats with uncontrolled diabetes in this study with
low plasma leptin concentrations were markedly hyper-
phagic. Insulin treatment increased plasma leptin and
reduced food intake. Schwartz et al. (37) have hypoth-
esized that insulin acts as a long-term signal to the
brain to regulate food intake. According to this model,
hypoinsulinemia resulting in reduced insulin delivery
to the central nervous system would contribute to
diabetic hyperphagia. In one study, these investigators
demonstrated that administration of insulin into the
third ventricle of STZ diabetic rats at doses that did not
alter peripheral insulinemia or plasma glucose levels
inhibited the diabetic hyperphagia by ,50% and de-
creased, but did not normalize, the overexpression of
neuropeptide Y (NPY) in the arcuate nucleus of the
hypothalamus (41). Hypothalamic NPY, a potent stimu-
lator of food intake (9), is upregulated in STZ diabetes
(24, 41, 47). Because central insulin administration did
not normalize food intake or NPY expression (41),
another factor in addition to hypoinsulinemia, possibly
decreased leptin, is likely to contribute to the hyperpha-
gia.
Leptin deficiency results in hyperphagia (6, 15, 33,
36, 44), and leptin administration decreases food intake
in rodents (6, 15, 33, 36, 44). Furthermore, hypotha-
lamic NPY expression is increased in leptin-deficient
(36, 39, 44) or leptin-resistant (8, 38) animals and is
decreased by leptin administration in leptin-deficient
or normal animals (36, 39, 44). Therefore, low circulat-
ing leptin concentrations may contribute, along with
hypoinsulinemia, to hyperphagia in unregulated diabe-
tes, perhaps via upregulation of the hypothalamic NPY
system. In the current study, low leptin concentrations
precede the onset of hyperphagia by several days.
Therefore, if hypoleptinemia does contribute to diabetic
hyperphagia, it is unlikely to be a fast-acting regulator.
Experiments with leptin administration in diabetic
animals will be necessary to test this hypothesis.
In summary, circulating leptin decreases markedly
and rapidly after the induction of STZ diabetes in rats.
Plasma leptin is restored by insulin administration in
proportion to the degree of glucose lowering. Reduc-
tions of circulating leptin in unregulated diabetes may
be a consequence of decreased adipocyte glucose uptake
and metabolism.
Perspectives
The present study, along with several previously
published experiments, provides evidence that insulin
and glucose are involved in regulating leptin produc-
tion and secretion. We have reported recently that the
uptake and utilization of glucose are key mediators of
insulin-stimulated leptin expression and secretion from
isolated adipocytes (31). Accordingly, changes of adipo-
cyte glucose metabolism may be involved in effects of
fasting and refeeding on circulating leptin concentra-
tions in vivo. Similarly, increased adipocyte glucose
metabolism resulting from insulin and glycemic re-
sponses to meals may contribute to the nocturnal rise of
leptin concentrations in humans and animals. The
biochemical mechanisms by which the metabolism of
glucose in adipose tissue may be linked to leptin
production are, however, not known. Although studies
investigating the actions of leptin have been almost
exclusively conducted in rodents, there is increasing
evidence that leptin may have a role in regulating
energy balance in humans (see Ref. 18). If this is the
case, a detailed understanding of the mechanisms
regulating leptin secretion may lead to new approaches
for treating obesity by augmenting endogenous leptin
production.
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